Published in Liver Transpl on February 01, 2015
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma patients awaiting liver transplantation. Liver Transpl (2015) 1.04
Wait Time of < 6 and > 18 Months Predicts Hepatocellular Carcinoma Recurrence after Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation (2017) 0.76
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl (2015) 0.75
Independent prognostic factors for posttransplant survival in hepatocellular carcinoma patients undergoing liver transplantation. Cancer Med (2016) 0.75
Reply: To PMID 25371111. Liver Transpl (2015) 0.75
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
caGrid: design and implementation of the core architecture of the cancer biomedical informatics grid. Bioinformatics (2006) 9.83
Consensus statement on the pathology of IgG4-related disease. Mod Pathol (2012) 9.01
Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med (2005) 6.88
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol (2006) 4.70
Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology (2007) 4.33
Mechanisms of hepatotoxicity. Toxicol Sci (2002) 4.13
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem (2006) 3.57
Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology (2011) 3.57
Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology (2006) 3.52
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. Am J Surg Pathol (2003) 3.36
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology (2010) 3.24
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23
Cholangiocarcinoma. Gastroenterology (2005) 3.15
Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients. Clin Gastroenterol Hepatol (2007) 3.14
Cellular and molecular mechanisms of liver injury. Gastroenterology (2008) 3.02
Lysosomes in cell death. Oncogene (2004) 3.00
Clinical features and management of splenic artery pseudoaneurysm: case series and cumulative review of literature. J Vasc Surg (2003) 2.94
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol (2007) 2.82
Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81
New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology (2013) 2.76
Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology (2002) 2.76
Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology (2012) 2.74
Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol (2007) 2.73
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg (2008) 2.66
EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc (2007) 2.61
Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56
Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55
Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51
Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology (2003) 2.45
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis (2002) 2.41
Life and death by death receptors. FASEB J (2009) 2.39
Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst (2010) 2.38
Cholangiocarcinoma. Clin Liver Dis (2008) 2.33
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (2012) 2.33
Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest (2014) 2.31
Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology (2011) 2.30
Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol (2003) 2.29
Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int (2012) 2.28
Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23
A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol (2004) 2.23
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19
Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18
Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis (2005) 2.18
Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective study. Am J Gastroenterol (2007) 2.14
Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl (2012) 2.14
Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol (2012) 2.09
A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol (2009) 2.06
Bronchial artery embolization : experience with 54 patients. Chest (2002) 2.05
Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg (2008) 2.04
Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem (2007) 2.01
Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell (2005) 2.01
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut (2007) 1.99
Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology (2002) 1.98
The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut (2006) 1.97
Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest (2010) 1.97
Controversies in clinical pancreatology: autoimmune pancreatitis: does it exist? Pancreas (2003) 1.96
Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest (2003) 1.96
Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab (2009) 1.94
Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology (2006) 1.93
Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol (2011) 1.92
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91
Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology (2006) 1.91
The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology (2008) 1.88
Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology (2003) 1.86
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl (2011) 1.85
Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol (2007) 1.83
A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol (2004) 1.83
JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem (2009) 1.82
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol (2004) 1.80
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78
Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest (2003) 1.73
Humanistic and economic impacts of hepatitis C infection in the United States. J Med Econ (2010) 1.72
miRNA expression in colon polyps provides evidence for a multihit model of colon cancer. PLoS One (2011) 1.72
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68
Distinctive pulmonary histopathology with increased IgG4-positive plasma cells in patients with autoimmune pancreatitis: report of 6 and 12 cases with similar histopathology. Am J Surg Pathol (2009) 1.68
Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut (2012) 1.67
Cephalexin-induced cholestatic hepatitis. J Clin Gastroenterol (2004) 1.66
A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol (2004) 1.66